Shopping Cart
- Remove All
Your shopping cart is currently empty
DSO-5a, a potent and selective orally active BB3 agonist, is a DMAKO-00 derivative that enhances ppar-γ activity via BB3 and stimulates ERK1/2 phosphorylation. It is utilized in diabetes-related research [1].

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 25 mg | $1,520 | 6-8 weeks | |
| 50 mg | $1,980 | 6-8 weeks | |
| 100 mg | $2,500 | 6-8 weeks |
| Description | DSO-5a, a potent and selective orally active BB3 agonist, is a DMAKO-00 derivative that enhances ppar-γ activity via BB3 and stimulates ERK1/2 phosphorylation. It is utilized in diabetes-related research [1]. |
| In vitro | DSO-5a (50 nM; 60min) induced IP-1 accumulation in hBB3-HEK cells with a pEC50 of 8.485 and elicited a potent calcium response with a pEC50 of 7.964 [1]. At 500 nM, it induced IP-1 accumulation in mBB3-HEK cells with a pEC50 of 7.262 and a calcium response with a pEC50 of 7.174 [1]. DSO-5a also activated ERK1/2 in both hBB3-H1299 and mBB3-HEK cells in a dose-dependent manner (0-100 nM) within 8 minutes [1]. |
| In vivo | DSO-5a (3-30 mg/kg; P.O.; 30 minutes) dose-dependently reduced glycemic variability in C57BL/6 mice [1], and at 10 mg/kg/day for 2-4 weeks, it lowered blood glucose levels in diabetic db/db mice [1]. |
| Molecular Weight | 440.45 |
| Formula | C23H24N2O7 |
| Cas No. | 2195411-63-1 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.